Becton Dickinson and Co (NYSE:BDX) EVP Simon D. Campion sold 2,903 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $236.94, for a total value of $687,836.82. Following the completion of the transaction, the executive vice president now directly owns 9,408 shares of the company’s stock, valued at $2,229,131.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
NYSE:BDX traded down $2.04 during trading hours on Friday, reaching $235.00. The stock had a trading volume of 39,132 shares, compared to its average volume of 1,298,341. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59. The company has a market capitalization of $63.79 billion, a P/E ratio of 21.34, a P/E/G ratio of 1.75 and a beta of 1.12.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.57 by $0.02. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The firm had revenue of $4.20 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same quarter in the previous year, the company posted $2.65 earnings per share. The company’s revenue was down .6% compared to the same quarter last year. As a group, analysts anticipate that Becton Dickinson and Co will post 11.69 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 7th will be issued a dividend of $0.77 per share. The ex-dividend date is Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.31%. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.
Several hedge funds have recently bought and sold shares of the business. Harvest Group Wealth Management LLC bought a new stake in shares of Becton Dickinson and in the 1st quarter worth approximately $25,000. Oregon Public Employees Retirement Fund boosted its position in shares of Becton Dickinson and by 22,485.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 6,545,502 shares in the last quarter. Pinnacle Financial Partners Inc. bought a new stake in shares of Becton Dickinson and in the 1st quarter worth approximately $29,000. RPG Investment Advisory LLC bought a new stake in shares of Becton Dickinson and in the 1st quarter worth approximately $32,000. Finally, Nalls Sherbakoff Group LLC bought a new stake in shares of Becton Dickinson and in the 4th quarter worth approximately $34,000. Hedge funds and other institutional investors own 84.58% of the company’s stock.
Several research analysts have issued reports on the company. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Monday, May 20th. Wells Fargo & Co dropped their price objective on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a research note on Monday, May 13th. Barclays upgraded Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price objective for the company in a research note on Monday, May 13th. BMO Capital Markets dropped their price objective on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research note on Friday, May 10th. Finally, Morgan Stanley dropped their price objective on Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating for the company in a research note on Friday, May 10th. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $255.31.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: What are the Benefits of Index Funds?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.